EyePoint Completes Enrollment for Phase 3 LUGANO Trial of DURAVYU in Wet AMD

EyePoint completes enrollment for phase 3 LUGANO trial of DURAVYU in wet AMD

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

EyePoint announces enrollment of LUGANO phase 3 trial

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

EyePoint Completes Enrollment in Phase 3 LUGANO Trial of Duravyu for Treatment of Wet AMD

EyePoint Pharmaceuticals announced it has enrolled and randomized over 400 patients in the phase 3 LUGANO pivotal trial of Duravyu for the treatment of wet age-related macular degeneration (AMD). Enrollment took 7 months. LUGANO is the first of two pivotal noninferiority trials underway in the phase 3 program of Duravyu for the treatment of wet AMD. Supported by the DAVIO 2 phase 2 clinical trial in over 160 patients, the phase 3 pivotal program…